As an organization that works predominantly in crisis-affected countries, generally in low- and middle-income countries, our experience in trying to access affordable medicines is that the way in which we get the price of these things down is through competition. This is really where we have seen the largest price reductions.
Look at the antiretroviral market for HIV treatments. For first-line antiretroviral therapies around the world where we now have really quite vibrant competition, we're probably approaching the lowest-sustainable price for these things. That's really what I think we need to be talking about: What is the sustainable price that ensures access, that is affordable for the patients and the health systems who need them, but is sustainable enough—in terms of manufacturing costs and a reasonable profit—to incentivize someone to be producing this and selling it?